Nutex Health reports its Q1 2026 results today carrying one of the more charged setups in small-cap healthcare: a stock that has surged 31% in a single month into a print where more than 13% of the free float is sold short.
The short position is both substantial and under moderate pressure from the price move. SI % of free float runs at 13.2% — well above any level that can be dismissed as noise — while days to cover of 7.3 adds a meaningful covering drag if sentiment shifts. Shares borrowed in the lending market have actually eased over the past month, down around 11%, though the past week saw a 2.8% uptick, consistent with fresh shorts being added into the rally. Cost to borrow is low at 1.72% APR, and availability in the lending pool is tight at roughly 45% of short interest — meaning bears can still get the borrow, but supply relative to demand has narrowed. ORTEX's short score of 73 places the stock in the 97th percentile for short-side conviction, a reading that has held firm across the past two weeks even as the price climbed.
The bull and bear cases revolve around a single, structurally unstable revenue line: arbitration payments. Bulls point to genuine operating momentum in the core hospital business — Q1 patient revenue per visit rose 37% year-over-year, gross margins expanded sharply to 56%, and reported EPS swung from a loss to $2.56. Bears counter that the arbitration-related revenue line has already fallen from $142 million to $105 million in one quarter, missing estimates along the way, and that the step-down in EPS from $11.12 in Q4 raises serious questions about what the normalized earnings base actually is. Analyst coverage is thin and stale — both Benchmark and Maxim Group carry Buy ratings with targets well above the current price, but the most recent analyst note dates to August 2025, making those targets limited guides at $119. The EV/EBITDA multiple of 4.1x and a PE of 6x suggest the market is pricing in further deterioration; the stock is optically cheap if arbitration revenues stabilize, and optically misleading if they don't.
Ownership adds texture to the setup. Thomas Vo, the founder and CEO, held 29% of shares as of early April and added to that position via a recent award. Topline Capital and BlackRock each hold above 5%. On the insider front, several senior officers made small open-market purchases in mid-March at prices around $88-94 — below the current level — while the CLO and CMO both sold modest amounts on the same day awards were granted, a pattern more consistent with routine compensation management than bearish conviction.
The earnings print is therefore squarely a test of where arbitration revenue lands, and whether management can articulate a credible floor — because with a 31% move in the stock and 13% of the float still short, the spread between a vindication and a capitulation is very wide.
See the live data behind this article on ORTEX.
Open NUTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
